TICKERNERD
Menu
KLRAHealthcare · Biotechnology

KLRA Stock Forecast: Kailera Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$17
−1.66% on the day

The 6 Wall Street analysts covering Kailera Therapeutics, Inc. hold a median 12-month price target of $41 — +138.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.2B
Ticker Nerd rank
1 / 100
Median analyst target
$41
Analysts covering
6
Total return, dividends reinvested
1W
−4.3%
1M
−6.7%
From high
−34.0%
From low
+2.6%
$17
$26
Range since 17 Apr 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

KLRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kailera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
36
Revisions
30
Momentum
13
Issuance
11
Growth
8
Value
8
Accruals
8
Quality
4
Volatility
4

Size (36): Smaller than most of the companies we track.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KLRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KLRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Apr 2026Adjusted close, US dollars
$10$20$30$40$50$60May 26Jun 26Jul 26Aug 26KLRAHigh $57Median $41Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $30Median $41High $57

The green dot is the last close — the median target sits +138.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 May 2026Evercore ISI GroupInitiatesOutperform—
12 May 2026JefferiesInitiatesBuy$48
12 May 2026JP MorganInitiatesOverweight$30
12 May 2026Leerink PartnersInitiatesOutperform$36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KLRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KLRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Kailera Therapeutics, Inc. (KLRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.6×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
2.0×

Cheaper than 47% of US stocks

EV / EBITDA
−4.2×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
41.8%

Higher than 91% of US stocks

Return on assets
−21.5%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KLRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KLRAKailera Therapeutics, Inc.$2.2B
1
VCELVericel Corp.$2.2B
94
GENBGenerate Biomedicines, Inc.$2.1B
1
HRMYHarmony Biosciences Holdings, Inc.$2.2B
83
ZYMEZymeworks, Inc.$2.1B
72
ADMAADMA Biologics, Inc.$2.2B
42
MRVIMaravai Lifesciences Holdings, Inc.$2.2B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kailera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KLRA news & analysis

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore

24/7 Wall Street · 18 Aug 2026positive

24/7 Wall Street reports on Kailera Therapeutics' IPO, noting the stock closed recently at $18.51, between a post-IPO high of $28.23 and a low of $16.39, with a market capitalization of $2.40 billion. The article frames the offering as a record-breaking obesity IPO.

Why it matters — The piece highlights KLRA's trading range and market valuation following its IPO, which is relevant for tracking the company's early public-market performance.

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 12 Aug 2026positive

Kailera Therapeutics reported its second quarter 2026 financial results and business updates. The IND for oral ribupatide is active with the U.S. FDA, with global Phase 3 obesity trials planned for the first half of 2027, and the ribupatide injection Phase 2b high-dose trial is fully enrolled with data expected in mid-2027. The company also expanded its executive team and expects its cash position to support clinical milestones into mid-2028.

Why it matters — KLRA watchers would care because the company is advancing its lead obesity candidate toward Phase 3 development with a fully enrolled Phase 2b trial and cash runway into mid-2028 to cover multiple upcoming clinical milestones.

FAQ

Frequently asked questions about KLRA stock

What is the KLRA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Kailera Therapeutics, Inc. have a median 12-month price target of $41, with estimates ranging from $30 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KLRA stock a buy right now?

Of the 6 analysts covering Kailera Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kailera Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KLRA?

As at 22 Aug 2026, Kailera Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (36 of 100).

Will KLRA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +138.8% from the last close, and Ticker Nerd's factor model ranks Kailera Therapeutics, Inc. 1 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KLRA stock forecast for 2030?

No analyst covering Kailera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KLRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $57 over the next 12 months.

What does Kailera Therapeutics, Inc. do?

Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on developing a diversified pipeline of GLP-1 therapies for obesity treatment. Headquartered in Waltham, Massachusetts, the company advances multiple clinical programs including ribupatide, its lead product candidate that functions as a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently in global Phase 3 trials.

What is the latest news on KLRA?

The most recent item we track (24/7 Wall Street, 18 Aug 2026): "Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore". 24/7 Wall Street reports on Kailera Therapeutics' IPO, noting the stock closed recently at $18.51, between a post-IPO high of $28.23 and a low of $16.39, with a market capitalization of $2.40 billion. The article frames the offering as a record-breaking obesity IPO.

Company

About Kailera Therapeutics, Inc.

Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on developing a diversified pipeline of GLP-1 therapies for obesity treatment. Headquartered in Waltham, Massachusetts, the company advances multiple clinical programs including ribupatide, its lead product candidate that functions as a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently in global Phase 3 trials. The company also develops oral and injectable formulations targeting various stages of obesity treatment, including KAI-7535, an oral small-molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera holds exclusive worldwide rights outside of China, Hong Kong, Macau, and Taiwan for its therapeutic candidates licensed from Jiangsu Hengrui Pharmaceuticals. The company recently completed its initial public offering and operates within the healthcare biotechnology sector, addressing obesity as a chronic progressive disease affecting over one billion people globally.

CEO Mr. Ronald C. Renaud Jr., M.B.A. · 145 employees · United States · https://www.kailera.com